Author Details

Nanotechnology has wide applications in many fields, especially in the field of biological sciences and medicines. In this review, study is mainly focused on the nanostructure of hydroxyapatite and its various applications in the field of pharmaceutical science. Nano hydroxyapatite has proved to be a boon in the field of biomedical science because of its property such as - biocompatibility, bioactivity, nontoxicity, noninflammatory, osteoconductivity. From this review one can definitely assemble knowledge about the making and characterization of Nano hydroxyapatite and its uses in the field of biomedical platform. This paper also collects information about the hydroxyapatite prepared from plant source by green synthesis mainly used for the study of antimicrobial action. Hydroxyapatite being bioactive in nature is highly compatible with the tissues and bones and has a very wide spectrum of activity to treat highly infectious disease such as cancer. Therefore the study is focused on its applicability to treat diseases such as bone cancer, bone diseases, microbial infection etc, also involving discussion on nanohydroxyapatite synthesis and its various applications.

Keywords

Hydroxyapatite, Nano Structure, Calcium Phosphate, Remineralising, Green Synthesis.

Full Text

References

Eric DK. Engines of creation: the coming era of nanotechnology. Anchor Book. 1986.

Vyas L, Gurjar J. Review on Nanotechnology and Its Future Aspects.

Narayan RJ, Kumta PN, Sfeir C, Lee DH, Choi D, Olton D. Nanostructured ceramics in medical devices: applications and prospects. Jom. 2004 Oct 1; 56(10):38.

Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. Journal of ethnopharmacology. 2005 Aug 22; 100(1-2):72-9.

Junqueira LC, Carneiro J, Kelley RO. Basic histology: text and atlas. New York: McGraw-Hill; 2003.

Habibah TU, Salisbury HG. Biomaterials, Hydroxyapatite.

Kalita SJ, Bhardwaj A, Bhatt HA. Nanocrystalline calcium phosphate ceramics in biomedical engineering. Materials Science and Engineering: C. 2007 Apr 1; 27(3):441-9.

Vance ME, Kuiken T, Vejerano EP, McGinnis SP, Hochella Jr MF, Rejeski D, Hull MS. Nanotechnology in the real world: Redeveloping the nanomaterial consumer products inventory. Beilstein journal of nanotechnology. 2015; 6:1769.

Kolmas J, Krukowski S, Laskus A, Jurkitewicz M. Synthetic hydroxyapatite in pharmaceutical applications. Ceramics International. 2016 Feb 1; 42(2):2472-87.

Kantharia N, Naik S, Apte S, Kheur M, Kheur S, Kale B. Nanohydroxyapatite and its contemporary applications. Bone. 2014; 34(15.2):1-71.

S. Bose, S. Tarafder, A. Bandyopadhayay, Hydroxyapatite coatings for metallic implants, in: M. Mucalo (Ed.), Hydroxyapatite (HAp) for Biomedical Applications, Wood head Publishing series in Biomaterials, Cambridge, UK,2015,pp.143–159.

Elliott JC, Mackie PE, Young RA. Monoclinic hydroxyapatite. Science. 1973 Jun 8; 180(4090):1055-7.

Kay MI, Young RA, Posner AS. Crystal structure of hydroxyapatite. Nature. 1964 Dec; 204(4963):1050.

Loo SC, Moore T, Banik B, Alexis F. Biomedical applications of hydroxyapatite nanoparticles. Current pharmaceutical biotechnology. 2010 Jun 1; 11(4):333-42.

Afshar A, Ghorbani M, Ehsani N, Saeri MR, Sorrell CC. Some important factors in the wet precipitation process of hydroxyapatite. Materials and Design. 2003 May 1; 24(3):197-202.

Loo SC, Siew YE, Ho S, Boey FY, Ma J. Synthesis and hydrothermal treatment of nanostructured hydroxyapatite of controllable sizes. Journal of Materials Science: Materials in Medicine. 2008 Mar 1; 19(3):1389-97.

Betke A, Kickelbick G. Bottom-up, wet chemical technique for the continuous synthesis of inorganic nanoparticles. Inorganics. 2014 Jan 27;2(1):1-5.

Sagadevan S, Dakshnamoorthy A. Synthesis and characterization of nano-hydroxyapatite (n-HAP) using the wet chemical technique. International Journal of physical sciences. 2013 Aug 30;8(32):1639-45.

Tas AC. Synthesis of biomimetic Ca-hydroxyapatite powders at 37 °C in synthetic body fluids. Biomaterials. 2000 Jul 1;21(14):1429-38.

Byrappa K, Yoshimura M. Handbook of hydrothermal technology. William Andrew; 2012 Dec 31.

López‐Macipe A, Gómez‐Morales J, Rodríguez‐Clemente R. Nanosized hydroxyapatite precipitation from homogeneous calcium/citrate/phosphate solutions using microwave and conventional heating. Advanced Materials. 1998 Jan; 10(1):49-53.

Ioku K, Yamauchi S, Fujimori H, Goto S, Yoshimura M. Hydrothermal preparation of fibrous apatite and apatite sheet. Solid State Ionics. 2002 Nov 1;151(1-4):147-50

Yan L, Li Y, Deng ZX, Zhuang J, Sun X. Surfactant-assisted hydrothermal synthesis of hydroxyapatite nanorods. International Journal of Inorganic Materials. 2001 Nov 1;3(7):633-7.

Riman RE, Suchanek WL, Byrappa K, Chen CW, Shuk P, Oakes CS. Solution synthesis of hydroxyapatite designer particulates. Solid State Ionics. 2002 Nov 1;151(1-4):393-402.

Wang YJ, Lai C, Wei K, Chen X, Ding Y, Wang ZL. Investigations on the formation mechanism of hydroxyapatite synthesized by the solvothermal method. Nanotechnology. 2006 Aug 14;17(17):4405.

Xin R, Ren F, Leng Y. Synthesis and characterization of nano-crystalline calcium phosphates with EDTA-assisted hydrothermal method. Materials and design. 2010 Apr 1;31(4):1691-4.

Bose S, Saha SK. Synthesis and characterization of hydroxyapatite nanopowders by emulsion technique. Chemistry of materials. 2003 Nov 18; 15(23):4464-9.

Olton D, Li J, Wilson ME, Rogers T, Close J, Huang L, Kumta PN, Sfeir C. Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials. 2007 Feb 1; 28(6):1267-79.

Liu TY, Chen SY, Liu DM, Liou SC. On the study of BSA-loaded calcium-deficient hydroxyapatite nano-carriers for controlled drug delivery. Journal of Controlled Release. 2005 Sep 20; 107(1):112-21.

Han YJ, Loo SC, Phung NT, Boey F, Ma J. Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153 Samarium-EDTMP doping. Journal of Materials Science: Materials in Medicine. 2008 Sep 1; 19(9):2993.

Fujiwara M, Shiokawa K, Morigaki K, Tatsu Y, Nakahara Y. Calcium phosphate composite materials including inorganic powders, BSA or duplex DNA prepared by W/O/W interfacial reaction method. Materials Science and Engineering: C. 2008 Mar 10; 28(2):280-8.

Matsumoto T, Okazaki M, Inoue M, Yamaguchi S, Kusunose T, Toyonaga T, Hamada Y, Takahashi J. Hydroxyapatite particles as a controlled release carrier of protein. Biomaterials. 2004 Aug 1; 25(17):3807-12.

Kandori K, Sawai S, Yamamoto Y, Saito H, Ishikawa T. Adsorption of albumin on calcium hydroxylapatite. Colloids and surfaces. 1992 Nov 17; 68(4):283-9.

Boonsongrit Y, Abe H, Sato K, Naito M, Yoshimura M, Ichikawa H, Fukumori Y. Controlled release of bovine serum albumin from hydroxyapatite microspheres for protein delivery system. Materials Science and Engineering: B. 2008 Feb 25; 148(1-3):162-5.

Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999 Sep 10; 285(5434):1733-7.

Ibrahim AR, Wei W, Zhang D, Wang H, Li J. Conversion of waste eggshells to mesoporous hydroxyapatite nanoparticles with high surface area. Materials Letters. 2013 Nov 1; 110:195-7.

Ishikawa K, Fujima N, Komura H. First‐order Raman scattering in MgO micro crystals. Journal of applied physics. 1985 Feb 1; 57(3):973-5.

Ignjatović NL, Penov-Gaši KM, Wu VM, Ajduković JJ, Kojić VV, Vasiljević-Radović D, Kuzmanović M, Uskoković V, Uskoković DP. Selective anticancer activity of hydroxyapatite/chitosan-poly (d, l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor. Colloids and Surfaces B: Biointerfaces. 2016 Dec 1; 148:629-39.

Kim HS, Kim HW. Fabrication and Raman studies of MgO/SnO2 core-shell heteronanowires. Acta Physica Polonica-Series A General Physics. 2009 Jul 1; 116(1):58.

Pathi SP, Lin DD, Dorvee JR, Estroff LA, Fischbach C. Hydroxyapatite nanoparticle-containing scaffolds for the study of breast cancer bone metastasis. Biomaterials. 2011 Aug 1;32(22):5112-22.

Krischok S, Stracke P, Höfft O, Kempter V, Zhukovskii YF, Kotomin EA. A comparative analysis of electron spectroscopy and first-principles studies on Cu (Pd) adsorption on MgO. Surface science. 2006 Sep 15; 600(18):3815-20.

Kumar R, Gokulakrishnan N, Kumar R, Krishna VM, Saravanan A, Supriya S, Somanathan T. Can Be a Bimetal Oxide ZnO—MgO Nanoparticles Anticancer Drug Carrier and Deliver? Doxorubicin Adsorption/Release Study. Journal of nanoscience and nanotechnology. 2015 Feb 1; 15(2):1543-53.

Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life sciences. 2005 Dec 22; 78(5):431-41.

Ren W, Qiao Z, Wang H, Zhu L, Zhang L. Flavonoids: promising anticancer agents. Medicinal research reviews. 2003 Jul; 23(4):519-34.

Hu ML. Dietary polyphenols as antioxidants and anticancer agents: more questions than answers. Chang Gung Med J. 2011 Sep; 34(5):449-60.

Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, Biedermann D, Markova L, Urban M, Sarek J. Pharmacological activities of natural triterpenoids and their therapeutic implications. Natural product reports. 2006; 23(3):394-411.

Lu JJ, Bao JL, Chen XP, Huang M, Wang YT. Alkaloids isolated from natural herbs as the anticancer agents. Evidence-Based Complementary and Alternative Medicine. 2012; 2012.

Pecere T, Gazzola MV, Mucignat C, Parolin C, Dalla Vecchia F, Cavaggioni A, Basso G, Diaspro A, Salvato B, Carli M, Palu G. Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. Cancer research. 2000 Jun 1; 60(11):2800-4.

Kikuchi T, Ishii K, Noto T, Takahashi A, Tabata K, Suzuki T, Akihisa T. Cytotoxic and apoptosis-inducing activities of limonoids from the seeds of Azadirachta indica (neem). Journal of natural products. 2011 Mar 7; 74(4):866-70.

Nahar L, Zahan R, Mosaddik A, Islam S, Haque A, Fazal A, Jesmin M. Antioxidant and antitumor activity of chloroform extract of Alangium salvifolium flowers. Phytopharmacology. 2012; 2(1):123-34.

Xu W, Li T, Qiu JF, Wu SS, Huang MQ, Lin LG, Zhang QW, Chen XP, Lu JJ. Anti-proliferative activities of terpenoids isolated from Alisma orientalis and their structure-activity relationships. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2015 Feb 1; 15(2):228-35.

Wu TS, Damu AG, Su CR, Kuo PC. Terpenoids of Aristolochia and their biological activities. Natural product reports. 2004; 21(5):594-624.

El-Wahab AE, Ghareeb DA, Sarhan EE, Abu-Serie MM, El Demellawy MA. In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC complementary and alternative medicine. 2013 Dec; 13(1):218.

Khan KH. Roles of Emblica officinalis in medicine-A review. Botany Research International. 2009; 2(4):218-28.

Jose JK, Kuttan G, Kuttan R. Antitumour activity of Emblica officinalis. Journal of Ethnopharmacology. 2001 May 1; 75(2-3):65-9.

Khan MT, Lampronti I, Martello D, Bianchi N, Jabbar S, Choudhuri MS, Datta BK, Gambari R. Identification of pyrogallol as an antiproliferative compound present in extracts from the medicinal plant Emblica officinalis: effects on in vitro cell growth of human tumor cell lines. International journal of oncology. 2002 Jul 1; 21(1):187-92.

Liu GF. Isolation and identification of antitumor constituents of diterpenoids lactone in Euphorbia fischeriana Steud. Zhong yao tong bao (Beijing, China: 1981). 1988 May; 13(5):35.

Itokawa H, Totsuka N, Nakahara K, Takeya K, Lepoittevin JP, Asakawa Y. Antitumor principles from Ginkgo biloba L. Chemical and pharmaceutical bulletin. 1987 Jul 25; 35(7):3016-20.

DeFeudis FV, Papadopoulos V, Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fundamental and clinical pharmacology. 2003 Aug; 17(4):405-17.

Pretner E, Amri H, LI W, Brown R, Lin CS, Makariou E, Defeudis FV, Drieu K, Papadopoulos V. Cancer-related over expression of the peripheral-type benzodiazepine receptor and cytostatic anticancer effects of Ginkgo biloba extract (EGb 761). Anticancer research. 2006 Jan 1; 26(1A):9-22.

Ding X, Bai D, Qian J. Novel cyclotides from Hedyotis biflora inhibits proliferation and migration of pancreatic cancer cell in vitro and in vivo. Medicinal Chemistry Research. 2014 Mar 1; 23(3):1406-13.

Miao L, Han N, Liu Z, Hu D, Yin J. Investigation of the chemical constituents and pharmacological functions of Ixeris sonchifolia (Bge.) Hance. Journal of Traditional Medicines. 2011; 6(5).

Li ZB, Wang JY, Jiang B, Zhang XL, An LJ, Bao YM. Benzobijuglone, a novel cytotoxic compound from Juglans mandshurica, induced apoptosis in HeLa cervical cancer cells. Phytomedicine. 2007 Dec 4; 14(12):846-52.

Matić IZ, Juranić Z, Šavikin K, Zdunić G, Nađvinski N, Gođevac D. Chamomile and marigold tea: Chemical characterization and evaluation of anticancer activity. Phytotherapy research. 2013 Jun; 27(6):852-8.

Ee GC, Lim CM, Rahmani M, Shaari K, Bong CF. Pellitorine, a potential anti-cancer lead compound against HL60 and MCT-7 cell lines and microbial transformation of piperine from Piper nigrum. Molecules. 2010 Apr 5; 15(4):2398-404.

Liu Y, Yadev VR, Aggarwal BB, Nair MG. Inhibitory effects of black pepper (Piper nigrum) extracts and compounds on human tumor cell proliferation, cyclooxygenase enzymes, lipid peroxidation and nuclear transcription factor-kappa-B. Natural product communications. 2010 Aug; 5(8):1253-7.

Christina AJ, Joseph DG, Packialakshmi M, Kothai R, Robert SJ, Chidambaranathan N, Ramasamy M. Anticarcinogenic activity of Withania somnifera Dunal against Dalton’s ascitic lymphoma. Journal of ethnopharmacology. 2004 Aug 1; 93(2-3):359-61.

De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet. 2010 Oct 2; 376(9747):1147-54.

Atkinson JM, Falconer RA, Edwards DR, Pennington CJ, Siller CS, Shnyder SD, Bibby MC, Patterson LH, Loadman PM, Gill JH. Development of a novel tumor-targeted vascular disrupting agent activated by MT-MMPs. Cancer research. 2010 Jul 27: canres-1440.

Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer research. 1997 May 15; 57(10):1829-34.

Jung SK, Lee MH, Kim JE, Singh P, Lee SY, Jeong CH, Lim TG, Chen H, Chi YI, Kundu JK, Lee NH. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR. Journal of Biological Chemistry. 2014 Dec 26; 289(52):35839-48.

Dieras V, Limentani S, Romieu G, Tubiana-Hulin M, Lortholary A, Kaufman P, Girre V, Besenval M, Valero V. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Annals of oncology. 2008 Apr 1; 19(7):1255-60.

Issell BF. The podophyllotoxin derivatives VP16-213 and VM26. Cancer chemotherapy and pharmacology. 1982 Apr 1;7(2-3):73-80.

Latruffe N, Delmas D, Jannin B, Malki MC, Passilly-Degrace P, Berlot JP. Molecular analysis on the chemopreventive properties of resveratrol, a plant polyphenol micro component. International journal of molecular medicine. 2002 Dec 1; 10(6):755-60.

Maiti A, Cuendet M, Croy VL, Endringer DC, Pezzuto JM, Cushman M. Synthesis and biological evaluation of (±)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. Journal of medicinal chemistry. 2007 Jun 14; 50(12):2799-806.

Chamberlain MC, Grimm S, Phuphanich S, Recht L, Zhu JZ, Kim L, Rosenfeld S, Fadul CE, Brain Tumor Investigational Consortium. A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC). Journal of neuro-oncology. 2014 Jun 1; 118(2):335-43.

Jaleel CA, Gopi R, Manivannan P, Panneerselvam R. Antioxidative potentials as a protective mechanism in Catharanthus roseus (L.) G. Don. plants under salinity stress. Turkish Journal of Botany. 2007 Jul 2;31(3):245-51.

Bernhardt P, McCoy E, O'Connor SE. Rapid identification of enzyme variants for reengineered alkaloid biosynthesis in periwinkle. Chemistry and biology. 2007 Aug 24;14(8):888-97.

Mattox K, INDUSTRY B. The Global Biomaterials Market Where Hard Tissue Biomaterials Fit In. BIOMATERIALS-Hard Tissue Repair and Replacement. 1992; 3.

Ravaglioli A, Krajewski A. Bioceramics: Materials· Properties· Applications. Springer Science and Business Media; 2012 Dec 6.

LeGeros RZ, LeGeros JP. Dense hydroxyapatite. In An introduction to bioceramics 1993 (pp. 139-180).

Vaccaro AR. The role of the osteoconductive scaffold in synthetic bone graft. Orthopedics. 2002 May 1; 25(5):S571-8.

Baggett, J. Bone Tissue. Available online: http://slideplayer.com/slide/1704473/ (accessed on 10 December 2015).

Park JB. Biomaterials science and engineering. Springer Science and Business Media; 2012 Dec 6.

Johnson KD, Frierson KE, Keller TS, Cook C, Scheinberg R, Zerwekh J, Meyers L, Sciadini MF. Porous ceramics as bone graft substitutes in long bone defects: a biomechanical, histological, and radiographic analysis. Journal of orthopaedic research. 1996 May; 14(3):351-69.

Parikh SN. Bone graft substitutes: past, present, future. Journal of postgraduate medicine. 2002 Apr 1; 48(2):142.

Wolford LM, Freitas RZ. Porous block hydroxyapatite as a bone graft substitute in the correction of jaw and craniofacial deformities. In Baylor University Medical Center Proceedings 1999 Oct 1 (Vol. 12, No. 4, pp. 243-246). Taylor and Francis.

Spivak JM, Hasharoni A. Use of hydroxyapatite in spine surgery. European Spine Journal. 2001 Oct 1; 10(2):S197-204.

Nery EB, Lynch KL, Hirthe WM, Mueller KH. Bioceramic implants in surgically produced infrabony defects. Journal of periodontology. 1975 Jun; 46(6):328-47.

Dent CE, Davies IJ. Calcium Metabolism in Bone Disease: Effects of Treatment with Microcrystalline Calcium Hydroxyapatite Compound and Dihydrotachysterol1. Journal of the Royal Society of Medicine. 1980 Nov; 73(11):780-85.

Jafari S, Maleki-Dizaji N, Barar J, Barzegar-Jalali M, Rameshrad M, Adibkia K. Methylprednisolone acetate-loaded hydroxyapatite nanoparticles as a potential drug delivery system for treatment of rheumatoid arthritis: In vitro and in vivo evaluations. European Journal of Pharmaceutical Sciences. 2016 Aug 25; 91:225-35.

Pepla E, Besharat LK, Palaia G, Tenore G, Migliau G. Nano- hydroxyapatite and its applications in preventive, restorative and regenerative dentistry: a review of literature. Annali di stomatologia. 2014 Jul; 5(3):108.

Moshaverinia A, Ansari S, Moshaverinia M, Roohpour N, Darr JA, Rehman I. Effects of incorporation of hydroxyapatite and fluoroapatite nanobioceramics into conventional glass ionomer cements (GIC). Acta biomaterialia. 2008 Mar 1; 4(2):432-40.

Structure of Bone Tissue. Availableonline:http://training.seer.cancer.gov/anatomy/skeletal/ tissue.html (accessed on 10 December 2015).

Huang S, Gao S, Cheng L, Yu H. Remineralization potential of nano-hydroxyapatite on initial enamel lesions: an in vitro study. Caries research. 2011; 45(5):460-8.

Moshaverinia A, Ansari S, Movasaghi Z, Billington RW, Darr JA, Rehman IU. Modification of conventional glass-ionomer cements with N-vinylpyrrolidone containing polyacids, nano-hydroxy and fluoroapatite to improve mechanical properties. Dental materials. 2008 Oct 1; 24(10):1381-90.

Huang S, Gao S, Cheng L, Yu H. Remineralization potential of nano-hydroxyapatite on initial enamel lesions: an in vitro study. Caries research. 2011; 45(5):460-8.

Huang SB, Gao SS, Yu HY. Effect of nano-hydroxyapatite concentration on remineralization of initial enamel lesion in vitro. Biomedical Materials. 2009 Jun 5; 4(3):034104.

Haghgoo R, Abbasi F, Rezvani MB. Evaluation of the effect of nanohydroxyapatite on erosive lesions of the enamel of permanent teeth following exposure to soft beer in vitro. Scientific Research and Essays. 2011 Nov 23; 6(28):5933-6.

Yamada M, Ueno T, Tsukimura N, Ikeda T, Nakagawa K, Hori N, Suzuki T, Ogawa T. Bone integration capability of nanopolymorphic crystalline hydroxyapatite coated on titanium implants. International journal of nanomedicine. 2012; 7:859.

Singh VP, Nayak DG, Uppoor AS, Shah D. Clinical and radiographic evaluation of Nano-crystalline hydroxyapatite bone graft (Sybograf®) in combination with bioresorbable collagen membrane (Periocol®) in periodontal intrabony defects. Dental research journal. 2012 Jan; 9(1):60.

Qu Y, Wang P, Man Y, Li Y, Zuo Y, Li J. Preliminary biocompatible evaluation of nano-hydroxyapatite/polyamide 66 composite porous membrane. International journal of nanomedicine. 2010; 5:429.

Yu J, Zhang W, Li Y, Wang G, Yang L, Jin J, Chen Q, Huang M. Synthesis, characterization, antimicrobial activity and mechanism of a novel hydroxyapatite whisker/nano zinc oxide biomaterial. Biomedical Materials. 2014 Dec 22;10(1):015001.

Kumar GS, Rajendran S, Karthi S, Govindan R, Girija EK, Karunakaran G, Kuznetsov D. Green synthesis and antibacterial activity of hydroxyapatite nanorods for orthopedic applications. MRS Communications. 2017 Jun;7(2):183-8.

Yang CC, Lin CC, Liao JW, Yen SK. Vancomycin–chitosan composite deposited on post porous hydroxyapatite coated Ti6Al4V implant for drug controlled release. Materials Science and Engineering: C. 2013 May 1;33(4):2203-12.

Ferraz MP, Mateus AY, Sousa JC, Monteiro FJ. Nanohydroxyapatite microspheres as delivery system for antibiotics: release kinetics, antimicrobial activity, and interaction with osteoblasts. Journal of biomedical Materials research Part A. 2007 Jun 15;81(4):994-1004.

Queiroz AC, Santos JD, Monteiro FJ, Gibson IR, Knowles JC. Adsorption and release studies of sodium ampicillin from hydroxyapatite and glass-reinforced hydroxyapatite composites. Biomaterials. 2001 Jun 1;22(11):1393-400.

Forsgren J, Brohede U, Strømme M, Engqvist H. Co-loading of bisphosphonates and antibiotics to a biomimetic hydroxyapatite coating. Biotechnology letters. 2011 Jun 1;33(6):1265-8.

A Comprehensive Review on PLGA-Based Nanoparticles used for Rheumatoid Arthritis

Abstract Views :156 | PDF Views:0

Authors

Sangeeta Mohanty ¹, Sthitapragnya Panda ¹, Debashis Purohit ¹, S. I. Sudam Chandra ¹

Affiliations
1 School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, IN

Source

Research Journal of Pharmacy and Technology, Vol 12, No 3 (2019), Pagination: 1481-1488

Abstract

Worldwide, Nanotechnology is frequently used for various applications in fields of medical science and therapeutics. However, biodegradable nanoparticles can improve the therapeutic value of various H2O soluble / insoluble drugs by improving solubility, bioavailability, retention time and protection of premature degradation of drugs in biological environment. In comparison to general Nanoparticles (NPs), encapsulation process with polymeric NPs are considered to be more fruitful and advanced as it provides better patient compliance. Since three decades through extensive research, polymers were first introduced as biodegradable or naturally dissolved surgical device. Current scenario utilizes polymeric based nanoparticles for the treatment of various ailments. Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease related to joints which hampers the normal life by exhibiting extra-articular manifestations. In-spite of major advances in drug therapies, still limitations are pervading with severe side effects in case of conventional drug delivery systems. Although different polymers are used for the preparation of Nanoparticles, utilization of USFDA and EMA approved Poly (lactic-co-glycolic acid) (PLGA) has gained much more popularity due to its unique features like low cytotoxicity, biocompatibility, biodegradability, targeted drug delivery, possibility of sustained release formulation and long biomedical applications. Nevertheless, researchers reveled that for targeted drug delivery, key factor involved is the persistance of NPs in systemic circulation of body. However, conventional NPs are rapidly opsonized and cleared through macrophages (fixed MPS) which is considered as foremost challenge in preparing these type of formulations. Hence, in order to overcome these problems, surface modification of conventional NPs with different molecules are needed so as to increase the circulation time and persistance of NPs in the blood. Furthermore, this review explores various key design parameters of RA targeted PLGA- based nanotechnology strategies in improving the treatment of rheumatoid arthritis. It comprehensively addresses various issues related to PLGA-based nanoparticles along with its method of preparation, surface modification and characterization techniques. Unlike usual drugs, nanoparticle drug delivery system aims at providing better patient compliance by delivering the drug to inflamed synovium by reducing systemic side effects.

Keywords

Rheumatoid Arthritis, PLGA Poly (Lactic-Co-Glycolic Acid), Nanoparticles, Adjuvant Induced Arthritis (AIA).

Full Text

References

Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. JPS. 2004; 96(3): 229-245.

Ferrero‐Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin‐1β generation. Clinical and Experimental Immunology. 2007; 147(2): 227-235.

Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-κB and upregulation of TRAIL receptors. Cancer Res. 2009; 69(23): 8958-8966.

Schurgers E, Billiau A, Matthys P. Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-γ. J Inter Cytok Res. 2011; 31(12): 917-926.

Mitragotri S, Yoo JW. Designing micro-and nano-particles for treating rheumatoid arthritis. Arch Pharmacal Res. 2011; 34(11): 1887-1897.

Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Current Opinion in Solid State and Materials Science. 2002; 6(4): 319-327.

Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. ISMRM. 2007; 25(4): 667-680.

Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and surfaces B: Biointerfaces. 2010; 75(1): 1-8.

Hussein MS, Zaytoun HA, Elshora OA, Elsabagh HM. Serum Level of Interleukin 34 in Rheumatoid Arthritis Patients: Relation to Disease Activity and Joint Destruction. Tanta Medical Sciences Journal. 2014; 9(3): 62-71.

Chiong HS, Yong YK, Ahmad Z, Sulaiman MR, Zakaria ZA, Yuen KH, Hakim MN. Cytoprotective and enhanced anti-inflammatory activities of liposomal piroxicam formulation in lipopolysaccharide-stimulated RAW 264.7 macrophages. Int J Nanomedicine. 2013; 8: 1245.

Heo R, Park JS, Jang HJ, Kim SH, Shin JM, Suh YD, Jeong JH, Jo DG, Park JH. Hyaluronan nanoparticles bearing γ-secretase inhibitor: in vivo therapeutic effects on rheumatoid arthritis. JCR. 2014; 192: 295-300.

Hofkens W, Grevers LC, Walgreen B, de Vries TJ, Leenen PJ, Everts V, Storm G, van den Berg WB, van Lent PL. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis. JCR. 2011; 152(3): 363-369.

Koning GA, Schiffelers RM, Wauben MH, Kok RJ, Mastrobattista E, Molema G, ten Hagen TL, Storm G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis. Arthritis and Rheumatism. 2006; 54(4): 1198-1208.

Komano Y, Yagi N, Onoue I, Kaneko K, Miyasaka N, Nanki T. Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis.JPET. 2012; 340(1): 109-113.

Zhou HF, Yan H, Senpan A, Wickline SA, Pan D, Lanza GM, Pham CT. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials. 2012; 33(33): 8632-8640.

Koo OM, Rubinstein I, Onyuksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharmaceutical research. 2011; 28(4): 776-787.

Chuan YP, Zeng BY, O’Sullivan B, Thomas R, Middelberg AP. Co-delivery of antigen and a lipophilic anti-inflammatory drug to cells via a tailorable nanocarrier emulsion. Journal of colloid and interface science. 2012; 368(1): 616-624.

Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. The Journal of rheumatology. 2010; 37(4): 692-703.

Mello SB, Tavares ER, Bulgarelli A, Bonfa E, Maranhao RC. Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis. Int J Nanomedicine. 2013; 8: 443.

Wilson DR, Zhang N, Silvers AL, Forstner MB, Bader RA. Synthesis and evaluation of cyclosporine A-loaded polysialic acid–polycaprolactone micelles for rheumatoid arthritis. European Journal of Pharmaceutical Sciences. 2014; 51: 146-156.

Satya Prasad M, Padmaja phaniNV, Nadiya Sk, Masthani Sk, Krishna Satya A. A Review on Role of Nanoparticles in Rheumatoid arthritis therapy, Department of Biotechnology, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur, Andhra Pradesh, India. IJRPB. 2016; 4(6): 2320-3471.

Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976; 263(5580): 797.

Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000; 21(23): 2475-2490.

Mao S, Xu J, Cai C, Germershaus O, Schaper A, Kissel T. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. International Journal of Pharmaceutics. 2007; 334(1-2): 137-148.

Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine. 2009; 2(2): 219-232.

Liu M, Zhou Z, Wang X, Xu J, Yang K, Cui Q, Chen X, Cao M, Weng J, Zhang Q. Formation of poly (L, D-lactide) spheres with controlled size by direct dialysis. Polymer. 2007; 48(19): 5767-5779.

Nie H, Lee LY, Tong H, Wang CH. PLGA/chitosan composites from a combination of spray drying and supercritical fluid foaming techniques: new carriers for DNA delivery. JCR. 2008; 129(3): 207-214.

Mishima K. Biodegradable particle formation for drug and gene delivery using supercritical fluid and dense gas. Advanced drug delivery reviews. 2008; 60(3): 411-432.

Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Progress in polymer science. 2011; 36(7): 887-913.

Sharma D. Polymeric nanoparticles preparation techniques and applications for drug delivery system- a brief review, WJPR, 2017; 6(6): 256-282.

Choi JS, Seo K, Yoo JW. Recent advances in PLGA particulate systems for drug delivery. J of Pharm Investig. 2012; 42(3): 155-163.

Jeong YI, Shim YH, Choi C, Jang MK, Shin GM, Nah JW. Surfactant‐free nanoparticles of poly (DL‐lactide‐co‐glycolide) prepared with poly (L‐lactide)/poly (ethylene glycol). Journal of applied polymer science. 2003; 89(4): 1116-1123.

Ameller T, Marsaud V, Legrand P, Gref R, Barratt G, Renoir JM. Polyester-poly (ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties. Pharmaceutical research. 2003; 20(7): 1063-1070.

Nam YS, Park JY, Han SH, Chang IS. Intracellular drug delivery using poly (d, l-lactide-co-glycolide) nano-particles derivatized with a peptide from a transcriptional activator protein of HIV-1. Biotechnology letters. 2002; 24(24): 2093-2098.

Jain AK, Das M, Swarnakar NK, Jain S. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2011; 28(1): 1-45.

Betancourt T, Byrne JD, Sunaryo N, Crowder SW, Kadapakkam M, Patel S, Casciato S, Brannon‐Peppas L. PEGylation strategies for active targeting of PLA/PLGA nanoparticles. Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials. 2009; 91(1): 263-276.

Zhang X, Yu C, Sun X, Sun F, Liu J, Li X, Lee RJ, Liu N, Li Y, Teng L. Ketoprofen and MicroRNA-124 Co-loaded poly (lactic-co-glycolic acid) microspheres inhibit progression of Adjuvant-induced arthritis in rats. Int. J. Pharm. 2018; 552(1-2): 148-153.

Whitmore SE. Delayed systemic allergic reactions to corticosteroids. Contact Dermatitis. 1995; 32(4): 193-198.

Butoescu N, Seemayer CA, Foti M, Jordan O, Doelker E. Dexamethasone-containing PLGA superparamagnetic microparticles as carriers for the local treatment of arthritis. Biomaterials. 2009; 30(9): 1772-1780.

Khaled KA, Sarhan HA, Ibrahim MA, Ali AH, Naguib YW. Prednisolone-loaded PLGA microspheres. in vitro characterization and in vivo application in adjuvant-induced arthritis in mice. AAps Pharm Sci Tech. 2010; 11(2): 859-869.

Park JS, Yang HN, Jeon SY, Woo DG, Kim MS, Park KH. The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis. Biomaterials. 2012; 33(33): 8600-8612.

Cong Y, Quan C, Liu M, Liu J, Huang G, Tong G, Yin Y, Zhang C, Jiang Q. Alendronate-decorated biodegradable polymeric micelles for potential bone-targeted delivery of vancomycin. Journal of Biomaterials Science, Polymer Edition. 2015; 26(11): 629-643.

Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly (lactide)–tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials. 2006; 27(21): 4025-4033.

Patel C, Patel M, Patel N, Prajapati PH, Patel CN. Poly Lactic Glycolic Acid (PLGA) As Biodegradable Polymer. Research J. Pharm. and Tech. 2010; 3(2): 354-360.

Srivastava S, Patel S, Daharwal S.J., Singh D, Singh M. Rheumatoid Arthritis: An Autoimmune disease prevalent in females. Research J. Pharm. and Tech. 2016; 9(2): 170-172.

Username
Password
Remember me